UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_____________________
FORM
8-K
_____________________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): August 25, 2009
_____________________
ORAMED
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
(State
or other jurisdiction
of
incorporation)
|
000-50298
(Commission
File Number)
|
98-0376008
(IRS
Employer
Identification
No.)
|
Hi-Tech
Park 2/5 Givat Ram
PO
Box 39098
Jerusalem,
Israel 91390
(Address
of principal executive offices and zip code)
Registrant’s
telephone number, including area code: 972-2-566-0001
_____________________
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
ITEM
7.01
|
REGULATION
FD DISCLOSURE
|
On August
25, 2009, Oramed Pharmaceuticals Inc. issued a press release announcing that
Frost and Sullivan Honored Oramed Pharmaceuticals with the 2009 European Oral
Drug Delivery Technology Innovation Award.
A copy of
the press release is attached to this Current Report on Form 8-K as Exhibit 99.1
and is incorporated by reference herein.
|
ITEM
9.01
|
FINANCIAL
STATEMENTS AND EXHIBITS.
|
|
(d)
|
Exhibits
|
|
99.1
|
Press
Release dated August 25, 2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ORAMED PHARMACEUTICALS
INC.
|
|||
|
Dated:
August 25, 2009
|
By:
|
/s/
Nadav Kidron
|
|
|
Nadav
Kidron
|
|||
|
President,
CEO and Director
|
|||
Frost and Sullivan Honors Oramed
Pharmaceuticals
with the 2009 European Oral Drug Delivery Technology
Innovation Award
JERUSALEM, Israel, August 25
/PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc.
(OTCBB: ORMP.OB) ( http://www.oramed.com), a developer of oral delivery systems,
today announced that it is the
recipient of the 2009 Frost & Sullivan European Oral Drug Delivery
Technology Innovation Award.
Oramed Pharmaceuticals is
developing a platform technology to create oral delivery systems for drugs and
vaccines delivered via injection. Oramed focuses on the treatment of
diabetes through its proprietary flagship product, an Oral Insulin capsule that
is currently in Phase 2b clinical trials. Oramed’s research pipeline also
includes other product candidates, such as an Oral GLP-1 Analog
capsule.
"We are honored to receive
the 2009 European Oral Drug Delivery Technology Innovation Award," said Nadav
Kidron, Esq., Oramed’s CEO. “Being recognized for our leadership position in the oral
drug delivery field by Frost & Sullivan is an encouraging validation of our
progress.
Frost
& Sullivan's Technology Innovation Awards recognize companies in a variety
of regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service and strategic product development. Industry analysts compare
market participants and measure performance through in-depth interviews,
analysis and extensive secondary research in order to identify best practices in
the industry.
About
Frost & Sullivan
Frost
& Sullivan, the Growth Partnership Company, partners with clients to
accelerate their growth. The company's TEAM Research, Growth Consulting and
Growth Team Membership(TM) empower clients to create a growth-focused culture
that generates, evaluates and implements effective growth strategies. Frost
& Sullivan employs over 45 years of experience in partnering with Global
1000 companies, emerging businesses and the investment community from more than
30 offices on six continents. For more information about Frost & Sullivan's
Growth Partnerships, visit http://www.frost.com.
About
Oramed Pharmaceuticals
Oramed
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed’s technology is based on over 25 years of
research by top research scientists at Jerusalem’s Hadassah Medical Center. The
Company’s corporate and R&D headquarters are based in
Jerusalem.
For more information, please visit
www.oramed.com
Forward-looking
statements
Some of the statements contained in
this press release are forward-looking statements which involve known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks and
uncertainties related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from other
pharmaceutical or biotechnology companies; and the company’s ability to obtain
additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors that
could cause actual results, performance or achievements of the company to differ
materially from those expressed or implied in such forward looking statements.
The company undertakes no obligation to update or revise any forward-looking
statements.
Company
and Investor Relations Contact:
Oramed
Pharmaceuticals
Tara
Horn
USA:
1-646-240-4193
Int’l:+972-54-334-4318
Email:
Tara@oramed.com